Navigation Links
Multiple organ disease cured by genes

Researchers University of Pennsylvania report the first ever use of gene therapy, in dogs, to cure a gene involving multiple body organs.// Mucopolysaccharidosis VII (MPS) is one of a group of rare genetic disorders called lysosomal storage diseases. Other examples include Tay Sachs disease and Gaucher disease. MPS involves an enzyme defect, leading to blindness, heart disease, and loss of mobility.

Most humans with MPS die in childhood. Researchers at the University of Pennsylvania have carried out the first ever gene therapy for MPS in dogs born with the disease. This introduces a healthy version of the defective enzyme, beta-glucuronidase, into the animals' liver. Treated dogs gained weight normally, compared to untreated animals, and showed none of the expected health problems.

This is the first time gene therapy has been used for a disease involving multiple organs. It could replace the standard treatment - which is to give injections of the missing enzyme. The therapy could also be used to treat other lysosomal storage diseases.


'"/>




Page: 1

Related medicine news :

1. Naked DNA Vaccination May Conquer Arthritis and Multiple Sclerosis
2. Adult stem cells in treatment for Multiple sclerosis (MS)
3. Life Quality For Patients With Multiple Sclerosis
4. Effective Pain Relief For Patients Suffering From Multiple Sclerosis
5. The Link Between Hepatitis B Vaccine And Multiple Sclerosis Questioned
6. Hope For Patients With Multiple Sclerosis
7. Individuals Born In May At A Higher Risk Of Developing Multiple Sclerosis
8. Debating The Link Between Sex Hormones And Multiple Sclerosis
9. Warning Issued by FDA on consumption of the drug Tysabri used to treat Multiple Sclerosis
10. Decreasing Multiple Births By Single Embryo Transfers
11. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood Bank (TCBB), ... labor and delivery team at Women’s Hospital at Renaissance in Edinburg for their outstanding ... the hospital and decide to donate. , “Women’s Hospital at Renaissance has been ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and elimination ... safety and minimize the cost of development. In this webinar, sponsored by Molecular ... lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , In ...
(Date:4/28/2017)... ... ... Bill Howe started his sewer and drain company in 1980 focusing heavily ... team, the Bill Howe brand was born and they began cultivating their mission to ... the San Diego community in which they worked, lived and were raising their daughters. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Researchers at ... of ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled ... wearable activity and sleep monitoring solutions for the global scientific community. The company’s ...
(Date:4/28/2017)... ... 2017 , ... Intellitec Solutions announced the publication of a ... Dynamics GP solution that integrates to their PointClickCare EHR software package. With the ... Brooke Grove now has the capability to achieve its goal for a comprehensive ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)...  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... it will be participating in the Deutsche Bank Securities ... in Boston, Massachusetts on Wednesday, ... a.m. Eastern Time. A live webcast of ... Relations website at http://investor.zimmerbiomet.com .  The webcast will ...
(Date:4/20/2017)... April 20, 2017 Research and Markets has ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ... ... delivery technologies will rise from USD 20 Billion in 2015 to ... Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market ...
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
Breaking Medicine Technology: